Fungal diseases today represent a world-wide problem. Poor hygiene and decreased
immunity are the main reasons behind the manifestation of this disease. After COVID-19, an …

Invasive fungal infections are rapidly increasing, and the opportunistic pathogenic Candida
species are the fourth most common cause of nosocomial systemic infections. The current …

Background Candida albicans is a fungal pathogen causing human infections. Here we
investigated differential gene expression patterns and functional enrichment in C. albicans …

In 2022, the US Food and Drug Administration approved a total of 16 marketing applications
for small molecule drugs, which not only provided dominant scaffolds but also introduced …

The pharmaceutical industry had a glorious year in 2022, with a total of 37 new drugs
including 20 new chemical entities (NCEs) and 17 new biological entities (NBEs) approved …

Introduction In the face of increased frequency of non-albicans Candida vulvovaginitis (VVC)
reported worldwide, there is a paucity of effective oral and topical antifungal drugs available …

Aim: To explore the antifungal potential of Sanghuang mushroom, a traditional Chinese
medicine. Materials & methods: The antifungal properties and the potential mechanism of …

Objective Several topical and oral drugs are available for maintenance therapy of recurrent
vulvovaginal candidiasis (RVVC)(≥ 3 episodes of symptomatic Candida infection per year) …

With our better understanding of the pathogenesis of various diseases, more and more
drugs and biological products are being tried and tested every day. Roughly, around 40–50 …

A new method for the synthesis of heterocyclic systems containing tetrazole and
tetrahydroisoquinoline is developed via the performance of one-pot Ugi-azide and Heck …